Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The major complication of diabetes mellitus is accelerated atherosclerosis that entails an inflammatory process, in which
fractalkine
and monocyte chemotactic protein-1 (MCP-1) play a key role. We investigated the effect of diabetes-associated high glucose (HG) on these chemokines and signalling mechanisms involved in human aortic smooth muscle cells (SMC). Exposure of SMC to HG resulted in an increase of
fractalkine
and MCP-1 expression and the activated
mitogen-activated protein kinase
(
MAPK
) signalling pathway, a process associated with elevated oxidative stress. Transfection with decoy oligodeoxynucleotides identified the involvement of transcription factors activator protein 1 (AP-1) and nuclear factor kappa B (NF-kappaB) in the observed up-regulation of chemokines. The
MAPK
inhibitors blocked the phosphorylation of IkBalpha and c-jun, indicating the role of
MAPK
in NF-kappaB and AP-1 activation in SMC under HG conditions. The up-regulation of MCP-1 and
fractalkine
was associated with increased adhesive interactions between HG-exposed SMC and monocytes. Treatment of HG-exposed SMC with peroxisome proliferator-activated receptors alpha (PPARalpha) activators (fenofibrate and clofibrate) resulted in a reduction of mRNA and protein expression of MCP-1 and
fractalkine
. In conclusion, HG upregulates the expression of
fractalkine
and MCP-1 in SMC leading to increased monocyte-SMC adhesive interactions by a mechanism involving activation of
MAPK
, activator protein-1 (AP-1) and NF-kappaB. The increased expression of these two pro-inflammatory chemokines and the ensuing increased adhesion between SMC and monocytes may trigger the inflammatory process associated with further vascular complications of diabetes.
...
PMID:High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. 1913 43
CX3CL1
(
fractalkine
) has been shown not only to be neuroprotective but also may play a role in HIV-1-associated neuropathogenesis. In this study, we found that production of
CX3CL1
by human astrocytes stimulated with interleukin (IL)-1beta was inhibited in a concentration-dependent manner following pretreatment with the synthetic cannabinoid WIN55,212-2. The CB(2) receptor selective antagonist SR144528 significantly inhibited WIN55,212-2-mediated suppression of
CX3CL1
, suggesting a CB(2)-receptor-related mechanism. IL-1beta triggered the activation of p38 and
ERK1
/2 (p44/42)
MAP kinase
(
MAPK
) signaling pathways, but WIN55,212-2 mainly inhibited p38
MAPK
phosphorylation. This finding was mirrored in experiments using known inhibitors of these MAPKs, suggesting that the suppression of
CX3CL1
production by WIN55,212-2 involves inhibition of signaling via p38
MAPK
. Our results support the concept that synthetic cannabinoids have anti-inflammatory properties and that these agents may have therapeutic potential for certain neuroinflammatory disorders.
...
PMID:WIN55,212-2 inhibits production of CX3CL1 by human astrocytes: involvement of p38 MAP kinase. 1921 51
Fractalkine (FKN/
CX3CL1
) has been detected in synovial fluids from osteoarthritis (OA) patients. Additionally, low-level expression of the FKN receptor, CX3CR1, has been demonstrated in OA synovial lining. This study aimed to determine a biological function for this ligand/receptor pair in OA and to assess a potential signalling mechanism for FKN in this predominant synovial lining cell type, using chemotaxis assays, Western blotting and F-actin staining. Chemotaxis assays demonstrate that the chemokine domain of FKN effectively induces migration of OA fibroblasts. Consistent with this finding, visualization of F-actin demonstrates that 1 or 10 nM FKN induces noticeable reorganization of cytoskeletal structure in OA fibroblasts after 30 min stimulation with a maximal enhancement at approximately 2 h. In addition, Western blotting analysis demonstrates that FKN stimulates phosphorylation of the mitogen-activated protein (MAP) kinases p38,
c-Jun N-terminal kinase
(JNK) and extracellular-regulated kinase (ERK) 1/2 as well as the serine-threonine kinase Akt at Ser 473 and Thr 308. All these phosphorylation events occur in a time-dependent manner, with little or no activation within 1 min, and maximal activation occurring typically between 5 and 30 min. Moreover, inhibition of ERK 1/2 significantly reduces FKN-induced OA fibroblast migration. These results suggest that FKN is a novel chemoattractant for OA fibroblasts, consistent with FKN-induced alterations in cytoskeletal structure. In addition, FKN induces OA fibroblast signalling via the MAP kinases p38, JNK and ERK 1/2, as well as Akt.
...
PMID:Fractalkine functions as a chemoattractant for osteoarthritis synovial fibroblasts and stimulates phosphorylation of mitogen-activated protein kinases and Akt. 1930 40
Resistin is a cytokine and
fractalkine
(Fk) a cell adhesion molecule and chemokine that contribute to human vascular inflammation by mechanisms not clearly defined. We questioned whether resistin induces Fk expression in human endothelial cells (HEC), compared the effect with that of the pro-inflammatory cytokine, TNF-alpha, and evaluated the consequences of co-stimulating HEC with both activators on Fk induction and on the signalling molecules involved. We found that resistin up-regulated Fk expression at comparable level to that of TNF-alpha by a mechanism involving P38 and
JNK
MAPK
and NF-kappaB. Co-stimulation of cells with resistin and TNF-alpha did not increase Fk expression induced by every single inducer. Moreover resistin reduced the expression induced by TNF-alpha in HEC. The new data uncover Fk as a novel molecular link between resistin and inflammation and show that resistin and TNF-alpha have no additive effect in Fk up-regulation or on the signalling molecules implicated.
...
PMID:Resistin up-regulates fractalkine expression in human endothelial cells: lack of additive effect with TNF-alpha. 1935 2
Cx3cl1, also called
fractalkine
, is located at 19p12, and encodes the
chemokine (C-X3-C motif) ligand 1
protein. This protein contains 393 amino acids, and is the only member of the chemokine CX3C subfamily. CX3CR1 is the specific receptor of Cx3cl1, and the binding of this ligand and its receptor participates in a variety of physiological and pathological processes. Through employing microarray technology we demonstrated for the first time that Cx3cl1 was upregulated in osteogenic-induced rat bone marrow mesenchymal stem cells (BMSCs). To analyze the gene expression profiling of Cx3cl1 in osteogenic-induced rat BMSCs at different times, real-time quantitative polymerase chain reaction (real-time PCR) was used to assay Cx3cl1 mRNA. The results showed that the expression of Cx3cl1 in osteogenic-induced rat BMSCs increased consistently for 28 days with a peak at day 21, and Cx3cl1 may be correlated with osteogenic differentiation of BMSCs. Based on bioinformatic analyses, we hypothesize that Cx3cl1 may be beneficial to the formation of the osteoplastic microenvironment by regulating cellular distribution and aggregation, and by promoting cellular mutual induction and paracrine. Cx3cl1 may also be involved in osteogenic differentiation and bone formation of BMSCs through an increase in Runx2 transcription by activating p38 mitogen-activated protein kinase (
MAPK
).
...
PMID:Gene expression profiling of Cx3cl1 in bone marrow mesenchymal stem cells by osteogenic induction. 1942 92
Peripheral nerve injury leading to neuropathic pain induces the upregulation of interleukin (IL)-6 and microglial CX3CR1 expression, and activation of p38 mitogen-activated protein kinase (
MAPK
) in the spinal cord. Here, we investigated whether IL-6 regulates CX3CR1 expression through p38
MAPK
activation in the spinal cord in rats with chronic constriction injury (CCI) of the sciatic nerve. Similar temporal changes in the expression of IL-6, phosphorylated p38
MAPK
and CX3CR1 were observed following CCI. The increases in CX3CR1 expression, p38
MAPK
activation and pain behavior after CCI were suppressed by blocking IL-6 action with a neutralizing antibody, while they were enhanced by supplying exogenous recombinant rat IL-6 (rrIL-6). rrIL-6 also induced increases in spinal CX3CR1 expression, p38
MAPK
activation and pain behavior in naive rats without nerve injury. Furthermore, treatment with the p38
MAPK
-specific inhibitor, SB203580, suppressed the increase in CX3CR1 expression induced by CCI or rrIL-6 treatment. Finally, blocking CX3CR1 or p38
MAPK
activation prevented the development of mechanical allodynia and thermal hyperalgesia induced by CCI or rrIL-6 treatment. These results suggest a new mechanism of neuropathic pain, in which IL-6 induces microglial CX3CR1 expression in the spinal cord through p38
MAPK
activation, enhancing the responsiveness of microglia to
fractalkine
in the spinal cord, thus playing an important role in neuropathic pain after peripheral nerve injury.
...
PMID:Interleukin-6 induces microglial CX3CR1 expression in the spinal cord after peripheral nerve injury through the activation of p38 MAPK. 1995 84
Following acute brain injury, albumin may gain access to the brain parenchyma. Clinical studies indicate a protective role for albumin in stroke but an increase in mortality associated with albumin administration following traumatic brain injury. We investigated the effects of albumin on astrocyte and microglial activation, and the role of mitogen-activated protein kinases (MAPK) in these responses. Albumin activated
ERK1
/2, p38 MAPK and
JNK
signaling pathways in astrocytes, and induced the production of interleukin (IL)-1beta, inducible nitric oxide (NO) synthase, the NO metabolite nitrite, and the chemokine
CX3CL1
while reducing the level of S100B. The release of inflammatory markers by astrocytes was partially dependent on p38 MAPK and
ERK1
/2 pathways, but not
JNK
. In microglia, albumin exposure activated all three MAPK pathways and produced an increase in IL-1beta and nitrite. Inhibition of p38 MAPK in microglia leads to an increased level of IL1beta, while inhibition of all three MAPKs suppressed the release of nitrite. These results suggest that albumin activates astrocytes and microglia, inducing inflammatory responses involved both in the mechanisms of cellular injury and repair via activation of MAPK pathways, and thereby implicate glial activation in the clinical responses to administration of albumin.
...
PMID:Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways. 1996 38
CX3CL1
/
fractalkine
, a chemokine specific to monocytes and NK cells, is induced synergistically by TNF-alpha and IFN-gamma in vascular endothelial cells. However, the mechanism for this synergism remains unclear. This study explored the hypothesis that the
CX3CL1
expression is regulated at a posttranscriptional level, which may responsible for the synergism between TNF-alpha and IFN-gamma. Brief exposure of HUVECs to TNF-alpha led to a robust increase in IFN-gamma-induced
CX3CL1
production. We found that TNF-alpha stabilized
CX3CL1
mRNA in HUVECs stimulated with IFN-gamma. Cloning of 3' untranslated region (UTR) of
CX3CL1
mRNA revealed the presence of a single copy of nonametric AU-rich element in its 3'UTR, and a luciferase reporter assay showed that a single AU-rich element is a crucial cis-element in the posttranscriptional regulation of
CX3CL1
. TNF-alpha treatment resulted in the phosphorylation of p38
MAPK
and its downstream target, MAPK-activated protein kinase-2, but IFN-gamma did not affect the levels of
MAPK
and MAPK-activated protein kinase-2 phosphorylation induced by TNF-alpha. Treatment of the cells with an inhibitor of p38
MAPK
accelerated the decay of
CX3CL1
mRNA induced by TNF-alpha or the combination of TNF-alpha and IFN-gamma. Immunoprecipitation assay revealed that mRNA stabilizer HuR directly binds to 3'UTR of
CX3CL1
mRNA.
CX3CL1
expression is under control of posttranscriptional regulation, which is involved in the synergistic induction of
CX3CL1
in response to the combined stimulation with TNF-alpha and IFN-gamma.
...
PMID:Characterization of synergistic induction of CX3CL1/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF-alpha in post-transcriptional regulation of CX3CL1. 2023 91
The chemokine
fractalkine
(
FKN
) is a critical mediator of spinal neuronal-microglial communication in chronic pain. Mature
FKN
is enzymatically cleaved from neuronal membranes and activation of its receptor, CX3CR1, which is expressed by microglia, induces phosphorylation of p38
MAPK
. We used CX3CR1 knockout (KO) mice to examine pain behaviour in the absence of
FKN
signalling. Naive CX3CR1 KO mice had normal responses to acute noxious stimuli. However, KO mice showed deficits in inflammatory and neuropathic nociceptive responses. After intraplantar zymosan, KO mice did not display thermal hyperalgesia, whereas mechanical allodynia developed fully. In the partial sciatic nerve ligation model of neuropathic pain, both mechanical allodynia and thermal hyperalgesia were less severe in KO mice than in wild-types (WT). Dorsal horn Iba1 immunostaining and phosphorylation of p38
MAPK
increased after injury in WT controls but not in KO animals. In WT mice, inflammation and nerve injury increased spinal cord CX3CR1 and
FKN
expression.
FKN
protein was also increased in KO mice following inflammation but not after neuropathy, suggesting the
FKN
/CX3CR1 system is differently affected in the two pain models. Loss of
FKN
/CX3CR1 neuroimmune communication attenuates hyperalgesia and allodynia in a modality-dependent fashion highlighting the complex nature of microglial response in pathological pain models.
...
PMID:Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. 2052 66
Lymphangioleiomyomatosis (LAM) is a progressive disease caused by accumulation of metastatic (LAM) cells in the lungs, lymphatics, and the tumor angiomyolipoma (AML). LAM cells have biallelic loss of either tuberous sclerosis complex gene (but predominantly TSC-2) and resultant dysregulation of the mammalian target of rapamycin (mTOR) pathway. Chemokines are associated with neoplastic cell growth, survival, and homing to specific organs and may play similar roles in LAM. Our objective was to study comprehensively the expression and function of chemokine receptors and how their function interacts with dysregulation of the mTOR pathway in LAM and AML. We used RT-PCR and FACS to study receptor expression in primary AML cells and immunohistochemistry to investigate expression in tissues. Chemokine receptor function was analyzed in AML cells by Western blotting of signaling proteins and cell proliferation and apoptosis assays. Primary AML cells, LAM, and AML tissues expressed CCR3, CXCR4, CXCR6, and CXC3CR1. In AML cells, their ligands CXCL12
CX3CL1
, CCL11, CCL24, and CCL28 caused robust phosphorylation of p42/44
MAPK
and Akt. CXCL12 was expressed in type II pneumocytes covering LAM nodules and caused AML cell growth and protection from apoptosis, which was blocked by AMD3100, a CXCR4 inhibitor. The mTOR inhibitor rapamycin, but not AMD3100, inhibited growth of AML tumor xenografts. We conclude that the CXCL12/CXCR4 axis promotes, but is not absolutely required for, AML/LAM cell growth and survival.
...
PMID:Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma. 2058 37
<< Previous
1
2
3
4
5
6
7
8
Next >>